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Neuroblastoma is a tumour of the neural crest derived sympathetic
nervous system, which in the UK accounts for 13% of paediatric
cancer deaths (Powell et al, 1998). The clinical behaviour
of the tumour varies widely, and although the International
Neuroblastoma Staging System (INSS) (Brodeur et al, 1993),
which attempts to classify the extent of disease based on clinical
and pathological characteristics, provides a useful guide to prog-
nosis, nevertheless tumour behaviour is still unpredictable in some
cases. Thus, patients with localized disease (INSS stages 1 and 2)
generally have excellent survival rates, but a proportion subse-
quently relapse and die of their disease. Similarly, the regression or
resolution, frequently cited as a characteristic feature of stage 4S
tumours in infants, is not always seen, and progressive fatal
tumour growth may also occur (Kerbl et al, 1996). In addition,
although widespread disease (stages 3 and 4) is very frequently
associated with an extremely poor prognosis, the pattern of disease
progression may be rapid, causing early death, or may follow a
more protracted course over several years. A small proportion of
stage 4 patients may be long-term survivors. 
The variability in tumour behaviour has led to the suggestion
that neuroblastoma comprises a heterogeneous group of develop-
mentally related neoplasms (Brodeur et al, 1997) that may be
assumed to have differing genetic aetiologies. The genetic
defect(s) underlying the development of neuroblastoma are not
well understood however, and the significance of the large number
of different chromosomal abnormalities seen in tumours is unclear.
Currently the only clinically useful genetic marker is amplification
of the MYCN oncogene. Amplification is seen in 20–30% of
primary untreated tumours (Bown et al, 1999; Guo et al, 1999),
and is very frequently associated with a poor outcome. 
More recent cytogenetic and molecular studies have identified a
number of additional recurrent chromosomal abnormalities of
varying frequency and prognostic significance. Deletion of chro-
mosome 1p occurs in approximately 30% of tumours (Caron,
1995; Fong et al, 1992) and is often observed in combination with
MYCN amplification. Chromosome 17q gain is observed in
approximately half of all tumours, and is associated with a low
survival rate (Bown et al, 1999), although this risk appears to be
modified by other factors such as MYCN amplification and
chromosome 1p deletion. Loss of heterozgyosity (LOH) and
comparative genomic hybridization (CGH) studies have impli-
cated chromosomes 3, 4, 11 and 14 (Brinkschmidt et al, 1998;
Caron et al, 1996; Ejeskar et al, 1998; Lastowska et al, 1997;
Plantaz et al, 1997; Vandesompele et al, 1998), but with the excep-
tion of chromosome 11 loss, which is most frequently observed in
advanced-stage tumours, prognostic significance is uncertain.
There is some evidence to suggest however, that loss on these 4
chromosomes is related and occurs in a defined subgroup of non-
MYCN amplified neuroblastomas (Bown et al, 1999; Guo et al,
1999; Plantaz et al, 1997). 
In this study we have carried out for the first time a detailed
investigation of the clinical significance of LOH on chromosomes
3, 4, 11 and 14 in a single patient group. We present evidence that
chromosome 11q LOH is highly predictive of disease progression,
irrespective of clinical stage. Furthermore our results are strongly
suggestive of the existence of 2 distinct subgroups of neuroblastoma,
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amplification of MYCN or chromosome 11q loss. 
PATIENTS AND METHODS 
Patients 
Tumour and matched normal tissue samples were collected from
28 patients presenting at the Birmingham Children’s Hospital
(UK) between 1992 and 1999 (out of a total of 66 patients treated
at the hospital during that period). Patients were selected for study
based on the availability of tumour material. There were 23
neuroblastomas, 4 ganglioneuroblastomas and 1 ganglioneuroma.
Tumour staging was carried out according to the International
Neuroblastoma Staging System criteria (Brodeur et al, 1993). The
details of all patients are summarized in Table 1. Tumour samples
were obtained prior to treatment in 23 cases, at relapse in 2, and 
for 1 ganglioneuroblastoma, the sample was obtained post-
chemotherapy. Early passage cell lines, established from 2 stage 4
tumours (including 1 diagnostic sample obtained prior to treat-
ment), were also used in this study. 
All patients were treated using standard European neuroblas-
toma protocols: LENSG 1994 for localized tumours in patients > 1
year, ENSG 8 for neuroblastoma in infants, ENSG 5 for stage 4
and MYCN-amplified tumours and ENSG 9 for stage 2B/3
tumours. With the exception of localized and stage 4S tumours, all
protocols include a chemotherapy regimen involving alternating
courses of vincristine 1.5 mg/m2, cisplatin 80 mg/m2, etoposide
200 mg/m2, and cyclophosphamide 600 mg/m2 (OPEC) and
vincristine, carboplatin 500 mg/m2, etoposide and cyclophos-
phamide (OJEC) prior to surgery. Additionally in the case of
ENSG5, surgery is followed by high-dose melphalan and autolo-
gous bone marrow or peripheral stem cell rescue. The median
follow-up time of the series was 29 months (range 4–73 months).
The study was approved by the regional Research Ethics
Committee and samples were obtained with appropriate informed
consent. 
LOH analysis 
DNA was extracted from tumours and corresponding normal
tissue (blood or lymphoblastoid cell lines) according to standard
methods. Tumours were selected on the basis of availability of
material. The pathology report for each sample was checked to
ensure that tumour cells were contained within the tissue.
Although each tissue sample may vary in tumour content from one
area to another, nevertheless the fact that all tumours were
collected from the same local centre did allow close liason with the
pathologist as to the requirements for molecular studies and
ensured that tissue from the centre of the specimen rather than the
margins was collected. 
Polymorphic markers from chromosomal regions 3p, 4p, 11q
and 14q were used to screen for LOH: D3S4550 3p24, D3S1767
3p22, D3S2408 3p21; D4S432, MSX1, D4S2375, D4S2366, all
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Table 1 Clinical and genetic characteristics of neuroblastoma patients 
Patient No. Stage Sex Age at diagnosis (years–months) Tumour histology* Outcome† NMA‡ 1p36 loss§ Chromosome 
3p 4p 11q 14q¶
11 1 m 0–4F H C R –– – – – –  
41 m 0 –10 FH CR –– – – – –  
13 1 f 1–0F H C R –– – – – –  
81 m 1 –2F H C R –– – – – –  
10 1 f 2–2F H C R –– – – – –  
27 1 m 4–5F H C R –– – – – –  
26 1 m 5–10 UH CR2 –– – – LOH – 
24 1 f 7–5F H C R –– – – – –  
34 2B m 1–4F H C R –– – – – –  
30 2B m 4–11 UH AWD –– – LOH LOH LOH 
54 S f 0 –2F H C R ––n.i. –– –  
21 3 m 0–10 UH CR – n.d. –– – –  
18 3 f 1–0F H C R – + – LOH LOH LOH 
23 4 m 2–4U H A W D ––LOH – LOH – 
28 4 m 2–6 n.d. DOD – + LOH LOH LOH – 
64 m 3 –0U H C R ––LOH LOH LOH – 
15 4 m 3–2 UH DOD ––LOH – LOH n.i. 
17 4 m 3–3 FH DOD – + LOH LOH LOH LOH 
74 m 3 –8 UH DOD –– – – LOH – 
14 4 m 3–9 UH DOD – + – LOH LOH – 
14 m 7 –10 UH DOD ––LOH LOH ––  
29** 4S m 0–1 FH DOD + + –– – –  
36** 4S m 0–5F H C R + –– – – –  
20 3 m 0–9U H C R + –– – – –  
22 4 m 0–10 UH DOD + + –– – –  
16 4 f 1–1 UH DOD + –– – – –  
31 4 f 2–6U H C R + + –– – –  
32 4 m 4–9U H A W D + + – LOH ––  
*FH/UH: favourable/unfavourable histology (Shimada); †CR: complete remission; CR2: 2nd remission; AWD: alive with disease; DOD: dead from disease; ‡NMA:
+: MYCN amplified, –: MYCN single copy; §+: 1p36 loss, –: 1p36 retention; ¶LOH: loss of heterozygosity; n.i.: not informative; –: retention of heterozygosity;
**patients 29 & 36 were stage 4S by INSS criteria, but were treated as stage 4 because of MYCN amplification and disease progression. 4p16; D11S2632 11q21, D11S1366 11q22, D11S1998 11q23,
D11S4464 11q24; D14S617, D14S1426, D14S118, all 14q32.
Data on the chromosomal localization of polymorphic markers
were extracted from the United Database for Human Genome
Mapping (http://bioinformatics.weizmann.ac.il/udb) (Chalifa–Caspi
et al, 1998). PCR products amplified from each normal/tumour
pair were run in adjacant lanes on 6% denaturing polyacrylamide
gels and were visualized by silver staining. LOH was scored where
at least one marker was informative and showed ≥ 60% reduction
in allele intensity as determined by densitometry. 
MYCN and chromosome 1p analysis 
MYCN status was determined by FISH using standard methods.
Tumours were considered to have amplified MYCN when copy
number was increased > 5-fold. Chromosome 1p status was
determined by LOH, and in most cases, also by FISH. 
Statistical analysis 
The Fisher’s exact test was used to examine associations between
LOH and stage, age, gender and MYCN status. The Kaplan–Meier
method and the log rank test were used to estimate overall and
event-free actuarial survival. Event-free survival was defined as the
time between diagnosis and the first clinical signs of disease
progression, or death without disease progression. In order to
determine the representativeness of the patient sample studied, chi-
square tests were used to compare the characteristics of cases used
in the study with those diagnosed in the same period, but for whom
material was unavailable. 
RESULTS 
LOH analysis 
We studied 28 paired samples of normal and tumour tissue for
LOH using markers mapping within recurrent regions of loss on
chromosomes 3p21–24, 4p16, 11q14–23 and 14q32 respectively.
MYCN amplification and chromosome 1p36 status were also
determined for all tumours (Table 1). The observed frequency of
LOH in the tumour panel was 22% on chromosome 3 (6 out of 27
informative samples), 29% on chromosome 4 (8 out of 28), 36%
on chromosome 11 (10 out of 28) and 11% on chromosome 14 (3
out of 27). Although the frequency of LOH was not high, never-
theless the pattern of loss was striking in two respects, firstly there
was a high degree of concordance between LOH on each of these 4
chromosomes: out of 10 tumours with chromosome 11q LOH, 5
also had LOH on at least 2 other chromosomes (Table 1). In addi-
tion it was noted that there was an almost complete absence of
LOH in MYCN-amplified tumours and a significant negative asso-
ciation between 11q LOH and MYCN amplification (P = 0.03).
These observations suggest that neuroblastomas with MYCN
amplification and those with LOH form 2 distinct groups in which
the molecular events associated with tumourigenesis differ. In the
latter group, LOH on chromosome 11q is most frequent and
appears to be the most critical event, although the recurrent
parallel loss on chromosomes 3, 4, and 14 suggests that these are
also significant alterations. 
There was no clear association between loss of chromosome
1p36 and LOH on other chromosomes. 1p36 loss was observed in
30% of tumours overall, with an approximately equal frequency in
MYCN-amplified tumours and the group of tumours showing
LOH on chromosomes 3, 4, 11 and 14. 
Prognostic significance of chromosome 11q LOH 
When considering the possible prognostic significance of the
observed genetic alterations, in view of the relatively small size of
the study it was important to ensure that our study population was
representative of neuroblastoma patients generally. In order to
exclude the possibility of sample bias, a comparison was made
between the clinical features of the patients studied with the
features of a further group of patients (n = 38) presenting during
the same time period, but not studied due to unavailability of
material. 
No significant differences were observed between the 2 groups
(cases studied vs cases not included) with respect to age (29%
were under 1 year of age in both groups) or gender (25% vs 34%
female, P = 0.59). We noted however, that high-stage tumours were
under-represented in the study sample, and low-stage tumours
were over-represented (due to the greater availability of the latter,
which are totally resected without chemotherapy). However, after
stratifying for low- and high-stage disease, no significant differ-
ence was found in the overall survival rate of the 2 groups (2-year
survival: 64% vs 66%, stratified log rank test, P = 0.93). We
conclude therefore that, while low-stage patients are over-repre-
sented in our sample, in terms of survival and other prognostic
factors, the group is typical of neuroblastoma patients in general
and sample bias is unlikely to have had a significant influence on
the associations observed. 
Among patients with single-copy MYCN, the occurrence of
chromosome 11q LOH was associated with advanced-stage
disease (P = 0.009) and also a reduction in both event-free 
(P = 0.0003) and overall survival (P = 0.006) as determined by
Kaplan–Meier analysis and a log rank test (Figure 1). The 2-year
event-free survival rate was only 30%, compared with 100%
among patients without 11q LOH. Similarly the overall survival
was reduced from 100% to 45%. Although the significance of
these observations must be treated with caution because of the
small sample size (n = 21), nevertheless the occurrence during the
total period of the study, of 5 deaths and 3 relapses among the 11q
LOH group (n = 10), in contrast to only 1 death among 11 patients
without 11q LOH is strongly suggestive of an important role for
genes on chromosome 11q in tumour progression/metastasis. 
It is of interest that although 11q LOH was associated predomi-
nantly with advanced-stage neuroblastoma, 2 patients with low-
stage tumours that showed 11q LOH, subsequently relapsed
(patients 26 and 30, Table 1). Both patients presented with similar
clinical features: age approximately 5–6 years at diagnosis, a
cervical/thoracic tumour (stage 1 or 2) with unfavourable
histology, and absence of MYCN amplification. Metastatic disease
was absent or was confined to local ipsilateral lymph nodes.
Disease remission was obtained in both cases following treatment
(surgery ± chemotherapy), but both patients subsequently relapsed
with either local (patient 30) or widespread disease (patient 26).
These observations suggest that 11q LOH may potentially provide
a very useful prognostic marker to identify a subgroup of patients
who have low-stage tumours but who are at high risk of relapse. 
The prognostic significance of LOH on chromosomes 3, 4 and
14 is more difficult to assess in view of the smaller number of
patients involved, and the very frequent co-occurrence with 11q
LOH. Only 2 patients showed LOH on chromosomes 3, 4 or 14 in
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amplified tumour showed chromosome 4 LOH. The second patient
(patient no. 1 in Table 1) showed LOH on both chromosomes 3
and 4. This boy had an atypical disease presentation, with diag-
nosis at approximately 8 years of age, of a stage 4 adrenal neurob-
lastoma with multiple lymph node and bony metastases, but
without bone marrow involvement. MYCN was not amplified.
Despite intensive treatment, several subsequent recurrences in
lymph nodes and bone eventually led to the patient’s death approx-
imately 6 years later. The final tumour specimen, which was still
negative for MYCN amplification, was obtained approximately 3
months before the patient’s death and was used for LOH studies. 
It is of interest that this is the only patient in our series, with a poor
outcome, who did not show either 11q LOH or MYCN amplifica-
tion, and this may have some significance in accounting for the
relatively protracted course of the disease. 
Comparison of clinical features of tumours with MYCN
amplification and 11q LOH 
Chromosome 11q LOH and MYCN amplification clearly define 2
biologically distinct subgroups of aggressive neuroblastoma that
appear to have different molecular aetiologies. It was of interest
therefore to determine whether these subgroups also showed clin-
ical differences. Table 2 shows the distribution of low- and high-
stage disease, age and gender among patients in each of these
genetic groups, as well as in the group of patients without genetic
alteration. The most significant difference (P = 0.015) observed
was age at diagnosis (Table 2). All 10 patients with 11q LOH
tumours were 1 year old or older, and 7 out of 10 were 3 years old
or older. In contrast, the average age of patients in the MYCN
amplified group was 1 year 6 months, with 4 out of 7 patients
younger than 1 year old. 
There were no significant differences in the MYCN amplified
and LOH patient groups with respect to other clinical characteris-
tics. However LOH tumours tended to occur at higher frequency in
non-adrenal/abdominal sites (3 out of 10 tumours) as compared
with MYCN-amplified tumours (0 out of 7 tumours), and also
showed a very marked male predominance (9 out of 10 patients).
These observations merit further investigation in a larger patient
population. 
DISCUSSION 
Accurate and reliable determination of probable prognosis is an
important factor in the selection of the most appropriate treatment
for children with neuroblastoma. In this study we have investi-
gated the frequency and prognostic significance of LOH in four
chromosomal regions that have previously been reported to be
non-randomly deleted in neuroblastoma (3p, 4p, 11q and 14q).
Our data represent the first detailed investigation in a single patient
group, of the combined pattern of LOH on all 4 chromosomes and
the relationship between LOH, MYCN amplification and chromo-
some 1p loss. 
A moderate level of LOH (11–36%) was observed in each chro-
mosomal region, with the highest frequency on chromosome 11.
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Figure 1 Overall survival (A) and event-free survival (B) for neuroblastoma
patients with MYCN amplification (n = 7), with 11q LOH (n = 10) or without
molecular abnormalities (n = 11). P-values for OS and EFS are 0.0196 and
0.0013 respectively for comparison of equality of survival distribution for all 3
patient groups, and 0.0057 (OS) and 0.0003 (EFS) for comparison of patients
with 11q LOH and those without molecular abnormalities
Table 2 Association between clinical and genetic characteristics of neuroblastoma patients 
Fisher’s Exact Test for Association (P) 
Clinical features MYCN amplification 11q LOH No alteration* All 3 groups 11q LOH vs no alteration 11q LOH vs MYCN amplification 
All cases 7 10 11 
Tumour stage 0.01 0.009 1.000 
1, 2, 4S 2 (29%) 2 (20%) 9 (82%) 
3,4 5 (71%) 8 (80%) 2 (18%) 
Age 0.029 0.090 0.015 
< 1 year 4 (57%) 0 (0%) 4 (36%) 
≥ 1 year 3 (43%) 10 (100%) 7 (64%) 
Gender 0.405 0.311 0.537 
Male 5 (71%) 9 (90%) 7 (64%) 
Female 2 (29%) 1 (10%) 4 (36%) 
*Tumours without MYCN amplification and without 11q LOH. These results are in close agreement with frequencies reported by
other workers (3p: 15%, Ejeskar et al, 1998; 4p: 23%, Caron et al,
1996; 11q: 32–44%, Srivatsan et al, 1993; Guo et al, 1999),
suggesting that our study population, although relatively small, is
representative of neuroblastoma patients generally. It is of interest
however, that much higher levels of LOH on chromosome 14
reported in 3 Japanese studies (30–50%) (Hoshi et al, 2000;
Suzuki et al, 1989; Takayama et al, 1992) are not evident in
European/US populations (18–23%, Fong et al, 1992; Srivatsan 
et al, 1993; Theobald et al, 1999) and may reflect the contribution
of tumours detected by mass screening. In the report of Hoshi 
et al (2000) for example, out of 17 neuroblastomas showing 14q
LOH, 10 were detected by mass screening. These 10 tumours were
all low stage in contrast to 6 out of 7 tumours not detected 
by screening, which were stage 3 or 4. This indicates that 14q
alteration may be a relatively early change in the development 
of neuroblastomas, but that additional alterations are required for
the acquisition of metastatic potential. 
An unexpected finding in our study was a very high degree of
concordance for LOH on chromosomes 3, 4, 11 and 14, strongly
suggesting that this pattern of alteration is associated with a
specific molecular pathway leading to neuroblastoma tumorigen-
esis. Furthermore, this pathway appears to be independent of
MYCN amplification. This latter observation is in agreement with
published reports noting an inverse correlation between MYCN
amplification and LOH on chromosomes 4p (Caron et al, 1996),
11q (Guo et al, 1999) and 14q (Fong et al, 1992; Theobald et al,
1999). Further evidence in support of this suggestion is also
provided by CGH studies. Vandesompele and co-workers for
example noted a significant positive association between losses of
11q and 3p, or 11q and 14q, occuring predominantly in tumours
without MYCN amplification (Vandesompele et al, 1998). 
The requirement for multiple genetic alterations in the develop-
ment of malignant tumours is widely accepted and a stepwise
progression from premalignant to malignant stages is well illus-
trated in the case of colorectal cancer for example, where many of
the alterations involved in the evolution of adenoma to carcinoma
have been identified (Gryfe et al, 1997). The identification of
premalignant lesions (neuroblastoma in situ) in fetal adrenal
glands, together with a high frequency of clinically silent neurob-
lastomas among tumours detected by screening of infants,
suggests that a similar process may occur in neuroblastoma.
Although in general the majority of these premalignant tumours
appear to be self-limiting, nevertheless in a small proportion, the
deletion of genes on 14q for example, may provide an early step
towards the acquisition of a more malignant phenotype. This is
consistent with the observation that chromosome 14q loss is not
predictive of survival (Fong et al, 1992; Takayama et al, 1992)
despite the fact that it is often associated with advanced stage 
of disease. In contrast, a significant association between 11q loss
and survival (Guo et al, 1999), suggests that this is a later event and
may be associated with increased invasive and metastatic potential. 
The results obtained in this study also show a very significant
association between 11q loss and poor outcome. (In at least 8 of
the 10 tumours showing LOH,  cytogenetic,CGH and 11p geno-
typing data confirmed that loss was specific to 11q and was not a
result of copy number abnormalities of the entire chromosome 11
(results not shown)). The 2-year overall survival rate was only 45%,
and was similar to that seen in the MYCN-amplified group (51%),
as compared with 100% survival in patients with single-copy
MYCN, without 11q loss. The similarity in survival rate between
MYCN and 11q LOH groups is consistent with the report of
Lastowska et al (2000). In a study of 80 tumours in patients in the
UK, Lastowska et al found that a distinct subgroup characterized
by absence of MYCN amplification and frequent deletion of 11q,
1p, 3p and 4p had a 3-year survival rate of only 28% as compared
with 24% for MYCN-amplified tumours and 100% for others.
These results are in contrast to the findings of Guo et al (1999,
2000), who reported that 11q LOH was associated with an inter-
mediate level of survival (2-year survival rate was 93%, 75% and
57%, for MYCN/11qLOH –/–, –/+ and +/– groups, respectively;
Guo et al, 2000). There are a number of possible reasons for this
difference. It may be significant that patients in the UK with
neuroblastomas tend to be diagnosed at an older age and with
higher stage disease than in other European countries and the USA
(Powell et al, 1998) and might therefore be expected to show a
poorer outcome. Patients with stage 4 disease make up approxi-
mately 60% of the total in the UK compared with approximately
40% elsewhere; the frequency of incidentally detected tumours is
also lower in the UK (Powell et al, 1998). Differences in European
and US treatment protocols may also have an effect on outcome.
All of these factors emphasize that the value of prognostic markers
is highly dependent on the characteristics of the patient population
to which they are applied and therefore must be tested indepen-
dently in each population. 
The observed differences in survival associated with 11q LOH
also allow some speculation about the characteristics of different
tumour subgroups. It is possible that 11q tumours show a more
progressive pattern of growth, with a longer lag period before clin-
ical symptoms become apparent. Thus 11q LOH tumours, if
detected at a relatively early stage of development, may have a
better prognosis if treated appropriately. In contrast, MYCN
amplification may produce an intrinsically more aggressive (and
also more chemo-resistant) tumour that develops very rapidly and
therefore is less likely to be detected prior to metastasis. These
tumours have a uniformly poor prognosis in all populations
studied. 
It is important to consider the relationship between 11q loss and
other molecular markers that have been shown to have prognostic
significance in neuroblastomas. The most important of these are
the loss of distal chromosome 1p and gain of 17q. In the case of
chromosome 17q gain, it is of interest that this indicator of adverse
outcome is observed in approximately 50% of both MYCN-
amplified and non-amplified tumours (Bown et al, 1999). It should
be noted however, that 17q gain very frequently arises as a result of
unbalanced chromosome translocation with loss of material from
the partner chromosome. Significantly, in MYCN-amplified
tumours, t(1;17) is a very frequent finding, while in non-amplified
tumours, chromosomes 3 or 11 may be involved in translocation
with chromosome 17. We have noted for example, that early
passage cell lines established from 2 of the 11q LOH patients
described in this study showed t(11;17) (patient 28) or both t(3;17)
and t(11;17) (patient 17), while the MYCN-amplified tumour of
patient 22 showed t(1;17). We conclude therefore that the prog-
nostic significance of chromosome 17q gain may be related at least
in part to the specific partner chromosome involved in the unbal-
anced chromosome 17 translocation. 
Although a close association between MYCN amplification and
1p36 loss is well established (Fong et al, 1989), the significance of
1p loss as an independent prognostic factor has been controversial
(Gehring et al, 1995; Maris et al, 1995). It is now becoming clear
however, that several different regions of loss are implicated and
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tions (1p36.2–36.3) are most frequently observed in patients with
a good prognosis; larger deletions including the same region, but
extending at least to 1p36.1 are associated with MYCN amplifica-
tion, and a further more distal region of deletion at 1p22 is
observed mostly in advanced-stage tumours (with and without
MYCN amplification) (Schleiermacher et al, 1994; Takeda et al,
1994; Caron et al, 1995; Cheng et al, 1995; Schleiermacher et al,
1996; Mora et al, 2000). In this study 1p deletion was observed
only in advanced-stage tumours, both with and without MYCN
amplification, with a trend towards more extensive deletion (1p36
to at least 1p22) in the latter (Genus et al, unpublished). A 1p dele-
tion was associated with a poor outcome in most cases. However
of 13 patients with progressive/fatal disease, only 6 showed 1p
deletion, whereas 12 out of 13 showed either 11q LOH or MYCN
amplification. We conclude therefore that 1p loss is a less useful
prognostic marker and that further investigation is required to
allow more precise definition of the critical region(s) of deletion
and the role played by each in tumorigenesis. 
In conclusion, our results are consistent with a proposed classifi-
cation of neuroblastomas into 3 distinct groups as outlined previ-
ously by Brodeur (1995), and in addition also provide a clear
molecular basis for this classification. Thus, group 1 comprises
low-stage tumours without MYCN amplification or other signifi-
cant structural abnormalities, which have a very favourable prog-
nosis. Group 2 tumours show 11q LOH (frequently accompanied
by LOH on chromosomes 3, 4 and/or 14), are frequently stage 3 or
4, and lack MYCN amplification. The prognosis in these cases may
be intermediate or poor. Group 3 tumours are characterized by
MYCN amplification, advanced stage and an extremely poor prog-
nosis. This system of classification has a number of important clin-
ical implications; these include the possibility to identify at
diagnosis most, if not all tumours with the potential for progressive
metastatic growth, and those that require immediate and aggressive
treatment. In addition the ability to distinguish between the
majority of stage 1 and 2 tumours with a low risk of relapse, and a
small but significant minority which are at high risk of relapse is an
important factor in improving overall survival rates. Finally, the
possibility that MYCN-amplified and 11q LOH tumours have
distinct aetiologies and clinical behaviours suggests that each group
should be considered separately in the optimization of treatment
protocols, and the assessment of clinical trial results. 
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